Dr. Andrew Evens to Lead UMass Memorial Cancer Research Office

National Lymphoma Expert to Serve as Medical Director and Deputy Director
for Clinical and Translational Research


FOR IMMEDIATE RELEASE

Date: March 21, 2011
Contact: Rob Brogna
508-793-5394
774-317-0422
Robert.brogna@umassmemorial.org  
Twitter: http://twitter.com/umassmemorial

WORCESTER - Andrew Evens, DO, MSc, has been named deputy director for clinical and translational research and medical director of the Clinical Research Office within the UMass Memorial Health Care Cancer Center of Excellence. He has also been named associate professor of medicine and will lead the Lymphoma Program at University of Massachusetts Medical School.

A national expert in the prognosis and treatment of non-Hodgkin's lymphoma and Hodgkin's disease/lymphoma, Dr. Evens joins UMass Memorial from the Northwestern University Feinberg School of Medicine in Chicago, where he had been since 2003. His responsibilities in this new role include leading the clinical and translational research efforts from the laboratories in the Medical School to the bedside in the Cancer Center of Excellence.

 "We are excited to welcome a clinical cancer investigator of the stature of Dr. Andy Evens," said Michael Blute, MD, director of the UMass Memorial Cancer Center of Excellence. "An internationally recognized leader in lymphoma clinical trials, Dr. Evens will lead the Clinical Research Office in the Cancer Center of Excellence. This important role will be responsible for all regulatory, compliance, safety and quality issues related to human subject cancer research.

Board certified in internal medicine, hematology and medical oncology, Dr. Evens attended Chicago College of Osteopathic Medicine and completed his residency and chief residency at Lutheran General Hospital and a hematology/oncology fellowship at Northwestern University Feinberg School of Medicine. Over the past 10 years, Dr. Evens has been principal investigator for a large number of hematology/oncology clinical trials and has published numerous articles with a particular emphasis on new treatments in lymphoma.